Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
126,882,307
-
Total 13F shares
-
39,031,389
-
Share change
-
+39,001,389
-
Total reported value
-
$379,749,744
-
Put/Call ratio
-
89%
-
Price per share
-
$10.10
-
Number of holders
-
56
-
Value change
-
+$379,446,712
-
Number of buys
-
55
Institutional Holders of Nautilus Biotechnology, Inc. - Common Stock, $0.0001 par value per share (NAUT) as of Q2 2021
As of 30 Jun 2021,
Nautilus Biotechnology, Inc. - Common Stock, $0.0001 par value per share (NAUT) was held by
56 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,031,389 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, Madrona Venture Group, LLC, RA CAPITAL MANAGEMENT, L.P., Comprehensive Financial Management LLC, Bain Capital Life Sciences Investors, LLC, ORBIMED ADVISORS LLC, Ally Bridge Group (NY) LLC, Amazon com Inc, Alyeska Investment Group, L.P., and Nantahala Capital Management, LLC.
This page lists
56
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.